<DOC>
	<DOCNO>NCT00887081</DOCNO>
	<brief_summary>Worldwide , several study report 4.4 % 85.4 % thalassemia patient positive anti hepatitis C antibody . Recently , three different study report efficacy safety combination therapy pegylated interferon ribavirin thalassemic patient . This study carry ahead assess impact combination therapy pegylated-interferon ribavirin large cohort italian patient beta thalassemia major - transfuse transfused , sickle cell disease sickle/beta-thalassemia .</brief_summary>
	<brief_title>Interferon Ribavirin Treatment Patients With Hemoglobinopathies</brief_title>
	<detailed_description>Infection common patient receive high number blood transfusion 1990 . The prevalence HCV infection high Italy , 70 % thalassemia major patient HCV-RNA positive . In Italy worldwide , genotype 1 frequent . Regarding prevalence cirrhosis , clinical data different cohort thalassemia patient show rate cirrhosis range 10 % 20 % . Male sex , high serum ALT value , positive serum test qualitative HCV-RNA significantly associate severe fibrosis cirrhosis . Cirrhosis related hepatitis C virus infection major risk factor development hepatocellular carcinoma major cause liver failure . An Italian study report clinical data 22 thalassemia patient hepatocellular carcinoma conclude development hepatocellular carcinoma associate presence cirrhosis , male gender , age 35 year , active HCV infection . Another prospective study report 2 % incidence new HCC follow-up 105 adult thalassemia patient cohort . Yet 2000 , several control trial report combination therapy alpha-interferon , give three time week , ribavirin , give every day , effective interferon alone.Recently , three different study report efficacy safety combination therapy pegylated interferon ribavirin thalassemic patient . Less extensive data present actually literature efficacy combination therapy pegylated interferon ribavirin HCV infect patient sickle cell disease sickle/beta-thalassemia .</detailed_description>
	<mesh_term>Hemoglobinopathies</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<criteria>Thalassemia Major Sickle Cell Disease Sickle/Beta Thalassemia patient Regularly transfuse ( hemoglobin ≥ 9.5 gr/dl ) transfuse , iron chelation regimen With positivity HCVRNA chronic liver disease without cirrhosis , naïve nonresponder relapser interferon monotherapy Thalassemia Major Sickle Cell Disease Sickle/Beta Thalassemia patient compensate liver failure heart failure Low white blood cell ( neutrophils &lt; 1.500/mmc and/or white blood cell &lt; 3.000/mmc ) Low platelet count ( &lt; 100.000/mmc ) Significant positivity Coombs test clinical serologic evidence immune hemolytic anemia , severe endocrinopathy , detection high titre autoantibody , coinfection HBV ( HbsAg positive )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>antiviral treatment hemoglobinopathy</keyword>
	<keyword>management chronic viral hepatitis C infection</keyword>
	<keyword>antiviral treatment</keyword>
</DOC>